To analyze usage and availability of sun protection devices, sun protection scores (SPUS and SPAS) were created. Points were given for subjects' responses regarding usage of sunscreen, sunglasses, hats/headgear, or shade structures. Sporadic use received 0 points, occasional use received 1 point, and routine use received 2 points.
Harris PA, Taylor R, Thielke R et al. (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. TO THE EDITOR Transforming growth factor-β (TGF-β) and platelet-derived growth factor (PDGF) are central mediators of fibrosis, and their overexpression contributes to the pathophysiology of scleroderma, chiefly by inducing the overproduction of extracellular matrix proteins (ECM) by dermal fibroblasts (Gay et al., 1989; Sargent et al., 2010; Bhattacharyya et al., 2012) . TGF-β also promotes the differentiation of dermal fibroblasts into myofibroblasts, which are key mediators of scleroderma (Abraham et al., 2007) . Thus, targeting this pathway is a reasonable strategy to treat a variety of fibrotic diseases including scleroderma, for which current treatment options are limited. Herein we explore the potential of novel mTOR inhibition as a means to block the pro-fibrotic effects of TGF-β. Recent studies have suggested a functional role of mTOR in fibrotic diseases
Accepted article preview online 2 July 2015; published online 6 August 2015
Abbreviations: ECM, Extracellular matrix; MTT, (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide); NHDF, Normal human dermal fibroblasts; PDGF, Platelet derived growth factor; TGF-β, Transforming growth factor-β and autoimmunity (Ong et al., 2007; Fried et al., 2008; Su et al., 2009; Raychaudhuri and Raychaudhuri, 2014) . This pathway is initiated by cytokines and growth factors that induce phosphorylation of Akt (Thr308) and its downstream mediators mTORC1, p70S6K1, and 4E-BP1. In addition to mTORC1, mTOR is now known to comprise a second multiprotein complex, mTORC2, which positively regulates the activity of mTOR through phosphorylation of Akt Ser473 (Bhagwat et al., 2011) . Blockade of mTORC1 has already been attempted as a treatment for scleroderma without much understanding about its molecular mechanism (Fried et al., 2008; Su et al., 2009; Yoshizaki et al., 2010) . Such strategies focused only on mTORC1 and did not account for the contributions of mTORC2 (Bhagwat et al., 2011) . To increase the effectiveness of mTOR blockade, dual inhibitors targeting both mTORC1 and mTORC2 have now been developed (Bhagwat et al., 2011) . Herein, we demonstrate that dual mTOR blockade can more effectively inhibit the pro-fibrotic effects of TGF-β and PDGF. These have therapeutic implications for scleroderma and other TGF-β dominant fibrotic diseases.
Antiproliferative effect of OSI-027, a dual mTOR inhibitor
The antimitotic effects of mTOR inhibition were evaluated using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay. Normal human dermal fibroblasts (NHDFs) were incubated with PDGF, a known NHDF mitogen, and cultures were treated with either OSI-027 or the mTORC1 inhibitor rapamycin. OSI-027 was found to be more effective at inhibiting PDGF-induced NHDF proliferation compared with rapamycin (Po0.05) ( Figure 1a ).
Expression of α-SMA, collagen I, and III
Apart from proliferating more, in response to TGF-β, NHDFs are known to differentiate into myofibroblasts and increase their production of ECM proteins. Thus, the expression of α-SMA (a marker of myofibroblasts) and the ECM-collagen I and III was determined by immunofluorescence microscopy (IF) following incubation with TGF-β (Abraham et al., 2007) . In comparison with rapamycin, OSI-027 was more effective at inhibiting TGF-β-induced α-SMA (Po0.01), collagen I (Po0.01), and collagen III (Po0.05) expression (Figure 1b and c) . Similarly, by quantitative PCR (qPCR), OSI-027 was found to be more effective at inhibiting TGF-β-induced upregulation of ACTA2 (Po0.005), COL1A1 (Po0.005), and COL3A1 ) and incubated for 3 days. Proliferation was determined by the MTT assay (n = 11). Immunofluorescence microscopy (IF, n = 6) and qPCR (n = 6) were conducted to determine the expression of α-SMA, collagen I, and collagen III at protein and mRNA level, respectively. (Po0.05) gene expression. OSI-027 was also able to reverse TGF-β-induced downregulation of MMP1 (Po0.05) (Figure 1d ).
Phosphorylation of mTOR kinases and Smad2
The ability of PDGF and TGF-β to alter mTOR signaling was confirmed using a luminex-based cell-signaling assay. Figure 1e and f demonstrated that TGF-β and PDGF were able to induce significant phosphorylation of Akt Ser473 (representing mTORC2 activity) and mTOR Ser2448 . As Smad signaling is critical for TGF-β-mediated induction of ECM (Bhattacharyya et al., 2012) , we determined the effect of OSI-027 on phosphorylation of Smad2. We found that TGF-β-induced phosphorylation of Smad2 was effectively inhibited by OSI-027 (Po0.05) (Figure 1g ). This provides an underlying molecular mechanism for the antifibrotic effects of dual mTOR inhibition.
Expression of mTOR kinases in scleroderma
On the basis of the in vitro data, we sought to evaluate whether mTOR was expressed in lesional skin of scleroderma patients. Immunohistochemical staining (Figure 2a) Although there are few studies suggesting the antifibrotic properties of rapamycin, chiefly a mTORC1 inhibitor (Ong et al., 2007; Fried et al., 2008; Su et al., 2009; Yoshizaki et al., 2010; Tamaki et al., 2014) , to date, there have been no detailed mechanistic studies on mTOR's role in TGF-β-mediated fibrotic pathways. Moreover, in cancer biology, it is becoming increasingly evident that targeting only mTORC1 does not completely inhibit this cascade (Figure 2b ). To overcome this deficiency, dual mTOR (mTORC1/mTORC2) inhibitors have been developed--e.g. OSI-027 (Bhagwat et al., 2011 )--and are currently being evaluated in a phase I trial for solid cancers (https://clinicaltrial.gov/ct2/show/ NCT00698243?term = OSI-027&rank = 1). Herein using an in vitro system, we demonstrated the ability of dual mTOR inhibition to reverse TGF-β and PDGF-mediated fibrotic processes more efficiently compared with rapamycin and elucidated the underling molecular mechanism. Considering the crucial role of PDGF and TGF-β in the pathogenesis of scleroderma, our results support the development of dual mTOR inhibitors for scleroderma and other TGF-β-mediated fibrotic diseases.
Normal human dermal fibroblast (NHDF)
Third to sixth passage NHDFs (ATCC PCS-201-012) were cultured at 37°C per 5% CO 2 in DMEM containing 10% FBS and 1% antibiotic-antimycotic. Cells were incubated in the presence or absence of PDGF (40 ng ml − 1 ), TGF-β (5 ng ml − 1 ) with or without rapamycin (10 nM), and OSI-027 (5 uM) for 3 days, which corresponded to their optimal concentrations. To measure proliferation, the MTT reagent was added and incubated at room temperature for 2 hours. Plates were read at 570 nm (Datta-Mitra et al., 2013) .
Immunofluorescence microscopy (IF)
NHDFs were processed for IF as described (Luna et al., 2011) . The data are represented as adjusted integrated density using Image J (NIH, Bethesda, MD).
Luminex assay

Expression of pAkt
Ser473
, pmTOR Ser2448 , pSmad2 Ser465/467 , corresponding total proteins, and β-actin was determined using the Bio-Plex Pro cell signaling kit (Bio-Rad) (Lang and Sandoval, 2014) . The phospho-proteins were normalized to respective total-proteins and represented as adjusted median fluorescence intensity (MFI).
Quantitative PCR
RNA was extracted using the RNeasy plus mini kit (Qiagen) and integrity determined by Agilent 2200 TapeStation. Total RNA was reverse transcribed using iScript, and qPCR was performed using customized PrimePCR plates (Bio-Rad, Hercules, CA). Reference genes used for normalization were GAPDH and HPRT1. Data were analyzed using the Bio-Rad CFX manager software (Bio-Rad) and expressed as fold change.
Skin biopsy
After obtaining IRB approved written informed consent, punch biopsies were obtained from three scleroderma patients with diffuse disease, and normal skin samples were obtained from discarded surgical skin.
Immunohistochemistry
Serial sections were deparaffinized and rehydrated and then immersed in 10 mM sodium citrate buffer. After antigen retrieval, endogenous peroxidase activity was blocked, and 10% BSA was used to TO THE EDITOR Kindler syndrome (KS) is a distinct type of epidermolysis bullosa (EB) defined by variable levels of skin cleavage and a progressive phenotype comprising skin blistering, photosensitivity, poikiloderma, mucocutaneous scarring, and malignancies (Has et al., 2011) . KS is caused by mutations in FERMT1, the gene encoding kindlin-1 (Jobard et al., 2003) . The particular features of KS may rely on the functions of kindlin-1, which is a member of the protein family of kindlins, essential integrin activators.
Kindlin-1 is engaged in integrin β1 adhesion complexes, the focal adhesions, and regulates β1 activation, dynamics, and adhesion turnover (Harburger et al., 2009; Margadant et al., 2012) . Besides, it acts as a linker between cell adhesion and regulation of the cell cycle (Patel et al., 2013) and controls Wnt and transforming growth factor-β availability to regulate stem cell proliferation (Rognoni et al., 2014). 
